BrightSpring Announces Pricing of Secondary Offering of Common Stock and Concurrent Share Repurchase
BrightSpring Health Services (NASDAQ: BTSG) priced a previously announced underwritten secondary offering of 20,000,000 shares at $41.15 per share, expected to close on March 4, 2026.
Rhea-AI Summary
BrightSpring Health Services (NASDAQ: BTSG) priced a previously announced underwritten secondary offering of 20,000,000 shares at $41.15 per share, expected to close on March 4, 2026. No shares are being sold by the company; selling stockholders will receive all proceeds.
The company authorized a concurrent repurchase of 1,464,807 shares from the underwriter at the offering price; the repurchase is conditioned on and expected to close simultaneously with the offering. Goldman Sachs is sole book-running manager and the offering relies on an S-3 shelf registration filed June 10, 2025.
Positive
- Concurrent repurchase of 1,464,807 shares authorized
- Underwriter will not receive fees on repurchased shares
- Offering priced at $41.15 for 20,000,000 shares
Negative
- Secondary sale of 20,000,000 shares increases public float
- BrightSpring will receive no proceeds from the offering
- Repurchase is conditioned on offering close and may not occur
Details
News Market Reaction – BTSG
In the Mar 3 session, BTSG declined 2.24%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Secondary shares
- 20,000,000 shares
- Selling stockholders’ underwritten secondary offering
- Offering price
- $41.15 per share
- Public offering price for secondary shares
- Company repurchase size
- 1,464,807 shares
- Shares to be repurchased concurrently from underwriter
- Offering close date
- March 4, 2026
- Expected closing date subject to conditions
- Last close price
- $41.58
- BTSG share price prior to news
- 52-week high
- $44.87
- Pre-news 52-week high level
- 52-week low
- $15.48
- Pre-news 52-week low level
- Shares outstanding (pre)
- 193,549,161 shares
- Pre-offering share count per 424B7 filing
Historical Context
-
Strong FY2025 results and 2026 guidance with revenue and EBITDA growth.
-
Announcement of detailed Investor Day with leadership presentations and Q&A.
-
Scheduling notice for Q4 and full-year 2025 results release and call.
-
Q3 2025 beat with raised full-year revenue guidance and higher EBITDA.
-
Secondary sale by holders with concurrent company repurchase of 1.5M shares.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
secondary offering financial
underwriter financial
underwriting fees financial
book-running manager financial
prospectus regulatory
preliminary prospectus supplement regulatory
public offering financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOUISVILLE, Ky., March 02, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex populations, today announced the pricing of the previously announced underwritten secondary offering by certain of its stockholders (the “Selling Stockholders”), including an affiliate of Kohlberg Kravis Roberts & Co. L.P. and certain members of management, of an aggregate 20,000,000 shares of common stock of BrightSpring, at the public offering price of
In addition, the Company has authorized, subject to the completion of the offering, the concurrent purchase from the underwriter, out of the 20,000,000 shares of common stock being sold as part of the secondary public offering, 1,464,807 shares of common stock at a price per share equal to the price per share to be paid by the underwriter to the Selling Stockholders. The underwriter will not receive any underwriting fees for the shares being repurchased by the Company. The closing of the share repurchase is conditioned on, and expected to occur simultaneously with, the closing of the offering. The offering is not conditioned upon the completion of the share repurchase.
Goldman Sachs & Co. LLC is acting as the sole book-running manager for the offering.
A shelf registration statement (including a prospectus) on Form S-3 relating to these securities was filed with the Securities and Exchange Commission on June 10, 2025 and became automatically effective upon filing. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering of these securities will be made only by means of a preliminary prospectus supplement and accompanying prospectus. Copies of the preliminary prospectus supplement and accompanying prospectus for the offering may be obtained from Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com.
Forward Looking Statements
The statements contained in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on BrightSpring’s current expectations and are not guarantees of future performance. The forward-looking statements are subject to various risks, uncertainties, assumptions, or changes in circumstances that are difficult to predict or quantify. These expectations, beliefs, and projections are expressed in good faith and BrightSpring believes there is a reasonable basis for them. However, there can be no assurance that these expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional, or local economic, business, competitive, market, regulatory, and other factors, many of which are beyond BrightSpring’s control. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in BrightSpring’s filings with the SEC under caption “Risk Factors,” including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and subsequent other filings BrightSpring makes with the SEC from time to time. Any forward-looking statement in this press release speaks only as of the date of this release. BrightSpring undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts
Investor Relations:
David Deuchler, CFA
Gilmartin Group LLC
ir@brightspringhealth.com
or
Media Contact:
Leigh White
leigh.white@brightspringhealth.com
502.630.7412
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.